Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists,
have significantly reduced morbidity and mortality associated with arterial thrombosis. Their …

Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules,
are currently the cornerstone of pharmacological treatment of atherothrombotic events …

Percutaneous coronary intervention (PCI) has become a standard-of-care procedure in
patients with acute and chronic coronary syndrome. Adjunctive antithrombotic therapy …

Background High platelet reactivity (HPR) is associated with subsequent thrombotic events
in patients undergoing percutaneous coronary intervention (PCI). Recently, the ABCD …

Background: The PARIS and CREDO-Kyoto risk scores were developed to identify patients
at risks of thrombotic and bleeding events individually after percutaneous coronary …

Ischemic heart disease and myocardial infarction contribute to the leading cause of death in
worldwide. The prevention and management of myocardial ischemia/reperfusion (I/R) injury …

Left atrial appendage closure (LAAC) are emerging treatment for patients with atrial
fibrillation (AF). However, data on the safety, efficacy, and medications for LAAC devices in …

Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the
cornerstone of the pharmacological treatment and prevention of atherothrombotic diseases …

Although reperfusion of the ischemic myocardium has been used as a vital treatment of
various patients with cardiovascular disease, the accompanying myocardial ischemia …

Background Gastrointestinal bleeding (GIB) is one of the most serious complications of
acute myocardial infarction (AMI) and is correlated with poor outcomes. Objective To …